Skip to navigationSkip to contentSkip to footerHelp using this website - Accessibility statement
  • Advertisement

    Rich list names hurt by cruel April for biotech stocks

    In April almost $1 billion was wiped from the combined market value of four well-regarded companies: Acrux, Mesoblast, QrXPharma and Prana Biotechnology, dragging down equally well known names such as Waislitz and Liberman.

    Jessica Gardner
    Jessica GardnerDeputy editor - News
    Updated

    Subscribe to gift this article

    Gift 5 articles to anyone you choose each month when you subscribe.

    Subscribe now

    Already a subscriber?

    The portfolios of some of Australia’s richest investors have been battered by the terrible start to the year experienced by biotechnology stocks.

    In April, almost $1 billion was wiped from the combined market value of four companies, Acrux , Mesoblast , QrXPharma and Prana Biotechnology , dragging down equally well known names like Waislitz, Liberman, Smorgon and Walker.

    Subscribe to gift this article

    Gift 5 articles to anyone you choose each month when you subscribe.

    Subscribe now

    Already a subscriber?

    Read More

    Latest In Healthcare & fitness

    Fetching latest articles

    Most Viewed In Companies